维普中文期刊产品整合服务
146篇 您的检索式:作者名="Leminen"
    题名 作者 年代 出处 被引量
1FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype显示文摘Haltia UM BO tzow R Leminen A 2014J Gynecol Oncol2014,25,1:1
2Ezrin immunoreacflvlty in relation to survival in serious ovarian patients显示文摘Moilanen J Lassus H Leminen A et at 2003Gynecol oneol2003,90,2:1
3Mifespritone may inhibit the mideyele gonadotropin surge at both ovarian and pituitary sites of action显示文摘HEIKINHEIMO O LEMINEN R RAIVIO T 2005Fertil Steril2005,84,5:1
4Gene amplification,mutation and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma显示文摘Lassus H Sihto H Leminen A 2006J Mol Med2006,84,8:1
5Ezrin immunoreactlvlty in relation to survival in serious ovarian patients显示文摘Moilanen J Lassus H Leminen A 2003Gynecol oneol2003,90,2:1
6Ezrin immunoreaetivity in relationship to survival in serous ovarian carcinoma patients显示文摘Moilanen J Lassus H Leminen A 2003Gynecol Oncol2003,90,2:1
7ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma显示文摘Lassus H Leminen A Vayrynen A 2004Gynecol Oncol2004,92,1:1
8Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety显示文摘LEMINEN H HURSKAINEN R 2012Int J Womens Health2012,4,:1
9A novel treatment of grade Ill acromioclavicular joint dislocations with a C-hook implant 显示文摘RYHANEN J LEMINEN A JAMSA T 2006Arch Orthop Trauma Surg2006,126,1:1
10Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma显示文摘Koivisto-Korander R Leminen A Heikinheimo O 2007Obstet Gynecol2007,109,2:1
11Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘 LASSUS H LEMINEN A 2003Gynecol Oncol2003,90,2:1
12Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous o- varian carcinoma显示文摘Lassus H Sihto H Leminen A 2006J Mol Med2006,84,8:1
13Pharmacokineticsof 10mg of mifepristoner显示文摘Leminen R Ranta S Von Hertzen H 2003Contraception2003,68,6:1
14Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients显示文摘MOILANEN J LASSUS H LEMINEN A 2003Gynecol Oncol2003,90,2:1
15Sociademo- graphic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97 显示文摘RISKA A LEMINEN A PUKKALA E 2003Int J Cancer2003,104,5:1
16Ezrin immunore- activity in relation to survival in serous ovarian carcinoma patienls显示文摘Moilanen J Lassus H Leminen A 2003Gynecol Oncol2003,90,2:1
17Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients 显示文摘Moilanen J Lassus H Leminen A 2003Gynecol Oncol2003,90,2:1
18Adenocarcinoma of theuterine cervix显示文摘Leminen A Paavonen J Forss M etal 1990Cancer1990,65,1:1
19Ezrin immu- noreactivity in relation to survival in serous ovarian car- cinoma patients 显示文摘Moilanen J Lassus H Leminen A 2003Gynecol Oncol2003,90,2:1
20Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma 显示文摘Lassus H Sihto H Leminen A 2006J Mol Med2006,84,8:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费